Cargando…
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
The development of proteasome inhibitors has been a major advance in therapy of multiple myeloma, accounting, in part, for the significant increase in the survival of patients diagnosed with this disease. Bortezomib was the first proteasome inhibitor to be approved for the therapy of multiple myelom...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467339/ https://www.ncbi.nlm.nih.gov/pubmed/31360084 http://dx.doi.org/10.2147/BLCTT.S82444 |